US health insurance is an obstacle to disease-modifying treatments in MS

Dennis Bourdette, Francesco Patti

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

In 1993, the first disease-modifying therapy (DMT) specifically for relapsing-remitting multiple sclerosis (RRMS) was introduced, and an untreatable disease became treatable. The US Food and Drug Administration now has approved 14 DMTs in 8 classes with different mechanisms of action, administration routes, and side effects.1 This therapeutic palette allows neurologists to control RRMS in most patients.

Original languageEnglish (US)
Pages (from-to)346-347
Number of pages2
JournalNeurology
Volume87
Issue number4
DOIs
StatePublished - Jul 26 2016

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'US health insurance is an obstacle to disease-modifying treatments in MS'. Together they form a unique fingerprint.

  • Cite this